[{"id":"5d6a13b7-0d2f-4bad-b517-6aad5b7c8e21","acronym":"","url":"https://clinicaltrials.gov/study/NCT01282463","created_at":"2021-01-18T05:12:09.851Z","updated_at":"2024-07-02T16:36:55.890Z","phase":"Phase 2","brief_title":"Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma","source_id_and_acronym":"NCT01282463","lead_sponsor":"Eli Lilly and Company","biomarkers":" KDR • FLT1 • VEGFB","pipe":"","alterations":" ","tags":["KDR • FLT1 • VEGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Cyramza (ramucirumab) • icrucumab (IMC-18F1)"],"overall_status":"Completed","enrollment":" Enrollment 148","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 02/01/2015","primary_completion_date":" 02/01/2015","study_txt":" Completion: 03/01/2015","study_completion_date":" 03/01/2015","last_update_posted":"2019-09-09"},{"id":"6a004d9a-9a48-49eb-b0bc-8965b21e5d31","acronym":"","url":"https://clinicaltrials.gov/study/NCT01234402","created_at":"2021-01-18T04:57:53.326Z","updated_at":"2024-07-02T16:36:56.917Z","phase":"Phase 2","brief_title":"Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients","source_id_and_acronym":"NCT01234402","lead_sponsor":"Eli Lilly and Company","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Cyramza (ramucirumab) • icrucumab (IMC-18F1)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 10/01/2013","primary_completion_date":" 10/01/2013","study_txt":" Completion: 07/01/2017","study_completion_date":" 07/01/2017","last_update_posted":"2019-08-14"}]